Format

Send to

Choose Destination
Nat Rev Cancer. 2003 Apr;3(4):303-9.

Improving the evaluation of new cancer treatments: challenges and opportunities.

Author information

1
Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232-6307, USA. mace.rothenberg@vanderbilt.edu

Abstract

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

PMID:
12671669
DOI:
10.1038/nrc1047
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center